New Models of Innovation in Life Sciences - MaRS Market Insights


Published on

Increasing costs and decreased productivity have hampered growth and investment in the global life sciences and health-care sector. The open-innovation approach embraced by many industries could transform the way biotech and health-care companies innovate—bringing products and services to market quickly and efficiently.

What does this mean for business and consumers in Ontario?

Presenting diverse perspectives, this breakfast panel examines the open-innovation approach and identifies opportunities and challenges for health-care stakeholders as they position themselves in the value chain. Learn how to use this approach and leverage it with success.

Published in: Business, Technology, Education
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

New Models of Innovation in Life Sciences - MaRS Market Insights

  1. 1. Pfizer CanadaTo Be Truly Healthy,It Takes More Than Medication
  2. 2. Innovation Gap
  3. 3. Innovation Gap!  “We intend to make our internal capability even more effective by tapping into the best scientific capability outside of our walls -wherever it exists. That’s why we are reaching out to scientists around the world.” Jeff Kindler, CEO, Pfizer
  4. 4. Understanding Disease Biology is not aCompetitive Activity
  5. 5. Canadian Public-Private Partnership Modelsof Innovation Pre-Competitive Partnership Models of Innovation Competitive Collaborative R&D Partnerships Centers of Excellence in Commercialization (CECRs) Quebec Pain Research Network (QPRN) Ontario Institute of Cancer Research (OICR) Center for Drug Research & Discovery (CDRD) Pre-Competitive R&D Partnerships Quebec Drug Discovery Consortium (CQDM) Structural Genomics Consortium (SGC)
  6. 6. Canadian Public-Private Partnership Modelsof Innovation World class science drives the day…… Very significant internal competition for global R&D $$s Local affiliates can drive internal global recognition of local opportunities, through local resources and local funds. Alignment with large consortia and public funding is very helpful IRMA : THE DRUG In the Future REPOSITIONING INITIATIVE Public-Private and Pre-competitive research is growing ON is in position to excel in this emerging paradigm Public support of PPP is not a temporary concept. Funding must be maintained, as a basis for attracting other $$s into the project.
  7. 7. Enable Integrate EngageA New Model for the Translation of Regenerative Medicine: Collaborative, Capital-Efficient Technology Development New Models of Innovation in Life Sciences April 20th, 2011, MaRS, Toronto Michael H. May PhD CEO Slide 1
  8. 8. “Open Innovation” is Not New OpenCollaboration Innovation Non-Zero-Sum GainTechnology Zero-Sum GainEnvironmentalStress or Need Competition “NONZERO – The Logic of Human Destiny”, Robert Wright Slide 2
  9. 9. Funding of Research andCommercialization in Canada Slide 3
  10. 10. CCRM Builds on MaRS and MI!"#$%&()*%&#+!#,-..-*%# /%%)/..0#*%#123# Slide 4
  11. 11. A Global Nexus for RM Technology and Commercialization Mission: To bridge the RM commercialization gap by leveraging funding and infrastructure, and mobilizing business and scientific expertise to translate technologies Existing IndustryGovernment Investment Programs Capital Pre- Clinical & Product Basic R&D Commercial Commercial Development Validation Validation Slide 5
  12. 12. Our Plan to Bridge the RM Commercialization Gap Existing IndustryGovernment Investment Programs Capital Enable Product Integrate Science and Create Links Development Business to Market Slide 6
  13. 13. Translation through Collaboration Slide 7
  14. 14.   capital efficient RM development  utilize academic infrastructure  facilitate global collaboration  focus on key bottlenecks  explore alternative funding sources Slide 8
  15. 15. Slide 9
  16. 16. Industry Engagement Platform 1 Platform 2 Platform 3 4 companies, 2 6 companies, 2 6 companies, 2Canadian, 2 large Canadian, 3 large Canadian, 1 large and 3 small and 3 small and 5 small Community Offerings Market Needs !  iPSC cells !  Lineage reprogramming Characterized and validated !  Stem cell characterization stem cell lines and standardization Clinical and commercial !  Cell culture bioprocesses, quantities of stem/differentiated sensors and scale-up / out cells !  Biomaterials/biocompatibility !  Therapeutic polymers Tissue mimetics for drug !  Microfabrication screening & transplantation !  Functional and stabilized, cell-derived tissues Foundational Reagents, tools and processes Slide 10
  17. 17. Driving Open InnovationCollaboration Non-Zero-Sum Gain "  Capital efficientTechnology "  Pre-competitive Zero-Sum GainEnvironmentalStress or Need Slide 11
  18. 18. evidence-based infection control
  19. 19. Evidence-based Infection Control!#$%"&()*+",-./0)$%"1%0-*"*2-34)*"3)*5%)6"$(*7"7-)(8/4/6"/*/6943(:"5)";)*5)%:";-/($%-:"/*1";8%)0-")$53);-(<"#$%"=)/6+">-68"/3.-0-"/*1"-?3--1"8/4-*5"(/2-59";8-%/40-("@"8%)%4-("A"B-/%("C$;$6/40-"D-/%**7+"E(-/(-"($%0-66/*3-"/*1"*2-34)*"3)*5%)6"()6$4)*(<"F "G)()3);/6"3/(-";/*/7-;-*5"F "H$5);/5-1"./*1".97-*-"3);86/*3-";)*5)%*7"F "H$5);/5-1")$5I%-/J"3)*5/35"5%/3*7""F "K>)5L(8)5M"1-*4N3/4)*"F "O-/6L4;-"@"($(5/*-1"5%/3J*7:"/6-%5("@";-5%3(" !"
  20. 20. Innovation in Healthcare...!Incremental innovation tends to be ‘evolutionary’. Small improvements in existing practices.!Disruptive innovation improves a product or service in ways that the market does not expect and looks to make significant impacts.!Goal in healthcare is affordability/sustainability while increasing accessibility, quality and safety. This sector should be an ideal target for disruptive solutions.! 3
  21. 21. Open Innovation!• C)*0-%7-*3-"Q)6$4)*"• R/%5*-%("S5."H67*-1"=)/6("• C)*N%;"&()*"/*1"R/5."• T/*5/*"5.-"&()*"• =-5M-%"E)*-" P"
  22. 22. !"#$%&"()*+",-"./&-"0--,1$2,-" 34&"5#"
  23. 23. 5#6",/&-"$77&%%"%70&-7&"•  8,9:&*"0-";<<="(,">&-&9$(&"?-,@A&*>&"$B,)("4):$-"/9,(&0-%"•  C&%)A(%"$-*"9&$>&-(%"0-(,"/)BA07"*,:$0-"@0(4,)("9&%(9072,-"•  D,"-,("EA&"F,9"GH",-"$-+"9&%)A(%"•  =<I",F">A,B$A",)(/)(",F"-&@"4):$-"$-*"/$9$%0(&"/9,(&0-"%(9)7()9&%"•  ;"/$/&9%"/&9"@&&?"
  24. 24. !"/)BA07J/901$(&"/$9(-&9%40/" @&*&-" H4$9:$"#$-$*$" .-($90," K&AA7,:&"39)%("
  25. 25. Industrial focus yields HQPFormer SGC members:•  > 65 scientists went on to jobs in academia •  15 to leadership positions (7 Faculty positions)•  > 33 to industry (9 to leadership positions)•  7 returned to the SGC/or relocated to another SGC site•  4 to business schoolsTraining at SGC:•  187 external scientists trained at the SGC (20 coop students)
  26. 26. No IP facilitates collaboration•  More than 200 Collaborations in 17 countries world wide•  ~250 publications – an average of 3.1 non-SGC scientists per paper 1 collaboration 2-5 collaborations >1000 expression clones have been sent 5-10 collaborations out during the past 3 years of which more 10-20 collaborations than 800 to academia > 20 collaborations
  27. 27. Knowledge transfer•  Over the last 3 years SGC scientists attended >250 conferences the majority of them as speakers•  Serve on SAB s of 5 biotech companies; 3 research consortia and 2 fundingagencies•  The SGC organised 20 workshops/conferences during the past three years•  More than 50 face-to-face meetings with industry per year•  More than 100 external scientists attended workshops held at SGC
  28. 28. Technology developmentSGC driven developments: !  Lex System !  BeeHive (w. MolSoft, Inovacia, CPR) !  iSee (MolSoft) !  Software for domain boundary analysis !  Expression clone generating platform !  Phage-resistant bacterial host strains !  Proximity assay!Testing and Improvement of a number of different products/machines in collaboration with vendors:Crystallisation: !  JCSG+ crystallization screen !  Mosquito crystallization robot !  Minstrel imaging robot !  Actor anti-icing lid !  SpearLab Liquid nitrogen handling dewars Compound screening !  Stratagene/Agilent RT-PCR !  Stargazer !  BMG Labtech multi-functional plate reader "Polarstar Omega“ !  Biacore with GE Healthcare Other !  Contur ELN
  29. 29. CommercializationHarbinger Biotech, founded in 2005, has sold equipment to over30 labs in industry and academia in Asia, North America andEuropeSGC software programs distributed to >40 labs1DegreeBio founded in 2010
  30. 30. Moving the Pre-Competitive Boundary H)BA07LH901$(&" H)BA07" G-*)%(9+" H$9(-&9%40/" D,:$0-" Chemical Target Drug Probes Validation Discovery Screening No IP (re)Screening Chemistry No restrictions Chemistry Structure Publication Lead optimization Bioavailability Pharmacology DMPK Toxicology Chemical development Clinical development Creative commons Proprietary
  31. 31. Impact of novel BET probe 250+ labs across the globeIdentified Published Distributed Jan 10 Sep 10 Jan 11